EFFICACY OF ROSUVASTATIN VERSUS ATORVASTATIN IN PATIENTS WITH DIABETES: RESULTS OF A SUBGROUP ANALYSIS FROM THE POLARIS STUDY

被引：0
|
作者：
Leiter, L. A. [1 ]
Sosef, F. [2 ]
Ycas, J. [3 ]
Melezinkova, H. [4 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada
[2] AstraZeneca, Molndal, Sweden
[3] AstraZeneca, Wilmington, DE USA
[4] AstraZeneca, Macclesfield, Cheshire, England
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2008年 / 9卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(08)70816-X
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：204 / 204
页数：1
相关论文
共 50 条
  • [41] Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis
    Zeng Liping
    Liu Xiufang
    Yang Tao
    Zhao Baomin
    Tuo Houshuai
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 31 (05) : 2203 - 2208
  • [42] COST-CONSEQUENCE ANALYSIS OF ROSUVASTATIN VERSUS ATORVASTATIN IN THE SPANISH SETTING
    Mata, P.
    Cortes, X.
    Marti, I
    Saborit-Canals, G.
    Pomares, E.
    VALUE IN HEALTH, 2022, 25 (01) : S118 - S118
  • [43] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Jeffrey J. Crowley
    Richard G. Langley
    Kenneth B. Gordon
    Andreas Pinter
    Laura K. Ferris
    Simone Rubant
    Huzefa Photowala
    Zhenyi Xue
    Tianshuang Wu
    Tianyu Zhan
    Stefan Beeck
    Megha Shah
    Richard B. Warren
    Dermatology and Therapy, 2022, 12 : 561 - 575
  • [44] Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
    Crowley, Jeffrey J.
    Langley, Richard G.
    Gordon, Kenneth B.
    Pinter, Andreas
    Ferris, Laura K.
    Rubant, Simone
    Photowala, Huzefa
    Xue, Zhenyi
    Wu, Tianshuang
    Zhan, Tianyu
    Beeck, Stefan
    Shah, Megha
    Warren, Richard B.
    DERMATOLOGY AND THERAPY, 2022, 12 (02) : 561 - 575
  • [45] Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with the metabolic syndrome: Results from the comets study
    Stalenhoef, AFH
    Wilpshaar, W
    Rose, H
    Sager, P
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 79 - 79
  • [46] Efficacy of high intensity atorvastatin versus moderate intensity atorvastatin for acute coronary syndrome patients with diabetes mellitus
    Liu, Zhi
    Xu, Yueqiao
    Hao, Hengjian
    Yin, Chunlin
    Xu, Ji
    Li, Jing
    Wang, Yanling
    Xu, Dong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 22 - 26
  • [47] Comparison of Efficacy of Atorvastatin and Rosuvastatin in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
    Shuja, Darab
    Mian, Muhammad Umar
    Dhanjal, Manpreet Kaur
    Mengar, Jaina
    Butt, Aqsa A.
    Chaudhari, Sandipkumar S.
    Wei, Calvin R.
    Khan, Areeba
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [48] Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin
    Olsson, A
    Southworth, H
    Wilpshaar, JW
    EUROPEAN HEART JOURNAL, 2001, 22 : 253 - 253
  • [49] COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN VERSUS GENERIC ATORVASTATIN IN PATIENTS AT HIGH CARDIOVASCULAR RISK IN SPAIN
    Brosa, M.
    Barrios, V
    Lobos, J. M.
    Serrano, A.
    Capel, M.
    Alvarez, C.
    VALUE IN HEALTH, 2011, 14 (07) : A380 - A380
  • [50] Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus - A subgroup analysis of the GREek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study
    Athyros, VG
    Papageorgiou, AA
    Symeonidis, AN
    Didangelos, TP
    Pehlivanidis, AN
    Bouloukos, VI
    Mikhailidis, DP
    ANGIOLOGY, 2003, 54 (06) : 679 - 690
12345